ANTX — AN2 Therapeutics, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1880438 ·
Last close
$4.23
Market Cap
$160.50M
52W High
$7.19
52W Low
$1.00
ADV30
287,052
Next earnings
—
AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis. It also develops AN2-502998 (AN15368), an investigational, boron-based small molecule in development for the treatment of chronic Chagas disease that is in preclinical trials; and has various research programs targeting the development of novel compounds in oncology and infectious disease based on its boron chemistry platform. It has a license agreement with Anacor Pharmaceuticals, Inc. to use, develop, manufacture, commercialize compounds and products, including epetraborole for the treatment, diagnosis, or prevention of various human diseases; and Brii Biosciences Limited to research, develop, manufacture, and commercialize compounds and products comprising epetraborole in China, Hong Kong, Taiwan, and Macau for the diagnosis, treatment, and prevention of human diseases; and GSK plc for the development of new therapies for TB. AN2 Therapeutics, Inc. was incorporated in 2017 and is headquartered in Menlo Park, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -8,670,000 -7,957,000 81,955,000 20,207,000 6,445,000
Jun 2026 0 — -8,904,000 -8,185,000 81,676,000 44,318,000 5,755,000
Mar 2026 0 — -10,551,000 -10,028,000 87,491,000 53,487,000 5,732,000
Dec 2025 0 — -9,316,000 -8,710,000 61,950,000 19,941,000 8,890,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-30,409,000
Investing CF
$-12,637,000
Financing CF
$45,250,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.93
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-267,120,000
Inventory
—
Receivables
—
ST Investments
$44,193,000
EBIT TTM
$-37,441,000
Pretax Income TTM
$-34,880,000
Interest Exp TTM
—
Analysts
2

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -38,109,000 -35,174,000 61,950,000 8,890,000 53,060,000 -29,834,000
Dec 2024 0 -54,554,000 -51,321,000 92,087,000 10,238,000 81,849,000 -49,257,000
Dec 2023 0 -69,635,000 -64,732,000 138,744,000 14,043,000 124,701,000 -53,288,000
Dec 2022 0 -42,262,000 -40,956,000 102,560,000 7,188,000 95,372,000 -33,462,000

TTM Snapshot

Revenues TTM
$2,535,000
NetIncome TTM
$-36,276,000
OpCashFlow TTM
—
Assets (Latest)
$81,676,000
Forward EPS
$-0.77

Peers — same industry

TickerNameMarket CapLastDaily %
ABEO ABEONA THERAPEUTICS INC. $160.27M $2.60 —
BCYC BICYCLE THERAPEUTICS PLC $162.10M $3.20 —
PRQR ProQR Therapeutics N.V. $162.29M $1.15 —
YARW Yarrow Bioscience, Inc. $163.04M $14.21 —
BBOT BridgeBio Oncology Therapeutics, Inc. $155.69M $1.94 —

News headlines (Yahoo Finance, 1h cache)

AN2 Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business and Scientific Highlights
2026-11-09 12:30 · Yahoo
AN2 Therapeutics to Present at Jefferies Global Healthcare Conference in London
2026-11-04 21:00 · Yahoo
AN2 Therapeutics Advances Pipeline With Development Candidate Nomination for Hypophosphatasia (HPP)
2026-11-04 12:00 · Yahoo
AN2 Therapeutics Receives U.S. FDA IND Clearance to Proceed with Planned Phase 2 Global Study of Oral Epetraborole in Polycythemia Vera
2026-11-02 12:00 · Yahoo
AN2 Therapeutics, Inc. Reports Inducement Grants Under Listing Rule 5635(c)(4)
2026-10-23 21:00 · Yahoo
AN2 Therapeutics to Present Phase 2 Design for Epetraborole in Polycythemia Vera at the 18th International Congress on Myeloproliferative Neoplasms
2026-10-21 11:00 · Yahoo
AN2 Therapeutics to Participate at Upcoming Investor Conferences
2026-10-20 20:13 · Yahoo
GSK (LSE:GSK) The Latest Update Raises A Bigger Question
2026-09-30 11:13 · Yahoo
AN2 Therapeutics Announces Extension of Funding for Tuberculosis Research Collaboration with GSK
2026-09-28 11:00 · Yahoo
AN2 Therapeutics, Inc. Reports Inducement Grants under Listing Rule 5635(c)(4)
2026-09-16 21:33 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.